Release date: 2017-08-09 Scientists respond to different conditions by modifying stem cells Type I diabetes is a blood genetic disease caused by the body's immune system. According to incomplete statistics, about 10% of every 422 million people have type 1 diabetes. In patients with this condition, the immune system will develop lesions and insulin production will be affected. In the past 15 years, researchers have been working to replace these confusing immune systems with human stem cells, so that the patient's insulin secretion returns to normal, and thus achieve a healing effect. Just last week, two patients with type 1 diabetes participated in the world's first treatment of diabetes based on embryonic stem cells. In the early days of the research, researchers encountered many obstacles. One of the main problems was how to make these stem cells play the expected role in patients. A medical company from San Diego, Viacyte, conducted research on this. They developed PEC-Direct, a stem cell extract, for human implantation, which is designed to induce islet cells that are destroyed by type 1 diabetes in patients. PEC-Direct will be placed under the skin of the human arm. The medical treatment is that whenever the patient's blood sugar rises, the implanted stem cell extract will secrete insulin to restore blood sugar to normal levels. “If this method works, we call it an 'effective antidote',†says Paul Laikind of Viacyte. “It can't be called a real antidote because it cures the symptoms and does not have a source of illness. (The patient's immune system) is healed, it only passively produces islet cells." In an early clinical trial, 19 patients were implanted with a device similar to PEC-Direct, which contained a smaller amount of stem cell extract than PEC-direct. When the device was implanted in the human body, the progenitor cells it contained did grow into stem cells, but this clinical trial did not have enough cells to test whether the device could treat type 1 diabetes. Now, PEC-Direct has been implanted in the body of two patients. The pores outside it allow blood to flow into the patient's blood vessels and excite the progenitor cells. When the progenitor cells are activated (about 3 months), it secretes stem cells according to the patient's needs and detects the patient's blood sugar level. If this method works, patients do not need to check their blood sugar at all times, and do not need to perform any insulin implantation. However, they do need to take in the drugs to stop the immune system from destroying the newly created stem cells. For nearly two decades, a treatment that uses a similar concept has been applied worldwide, and patients are treated by implanting donor islet cells. However, the small number of donors has greatly affected the number of audiences for the therapy. "If the method is successful, it will completely change the treatment of type 1 diabetes worldwide," said Emily Burns of the British Diabetes Charity Association. For stem cells, we don't need to worry about inventory at all. In this trial, embryonic stem cells were derived from an early embryo (provided by a woman who gave births using IVF technology). Since the progenitor cells of PEC-Direct are derived from embryonic stem cells, they can be replicated indefinitely. Laikind said the method would treat all patients with type 1 diabetes. James Shapiro of the University of Alberta in Canada helped Viacyte in the research of the project and has already donated his own islet cells for diabetics. He said: "If the cells that produce insulin are produced in unlimited quantities, then this It will be a major advancement in the treatment of diabetes, which will be a great milestone in the history of treating diabetes. "Type I diabetes is a blood genetic disease caused by the body's immune system. According to incomplete statistics, about 10% of every 422 million people have type 1 diabetes. In patients with this condition, the immune system will develop lesions and insulin production will be affected. In the past 15 years, researchers have been working to replace these confusing immune systems with human stem cells, so that the patient's insulin secretion returns to normal, and thus achieve a healing effect. Just last week, two patients with type 1 diabetes participated in the world's first treatment of diabetes based on embryonic stem cells. Scientists respond to different diseases by transforming stem cells In the early days of the research, researchers encountered many obstacles. One of the main problems was how to make these stem cells play the expected role in patients. A medical company from San Diego, Viacyte, conducted research on this. They developed PEC-Direct, a stem cell extract, for human implantation, which is designed to induce islet cells that are destroyed by type 1 diabetes in patients. PEC-Direct will be placed under the skin of the human arm. The medical treatment is that whenever the patient's blood sugar rises, the implanted stem cell extract will secrete insulin to restore blood sugar to normal levels. “If this method works, we call it an 'effective antidote',†says Paul Laikind of Viacyte. “It can't be called a real antidote because it cures the symptoms and does not have a source of illness. (The patient's immune system) is healed, it only passively produces islet cells." In an early clinical trial, 19 patients were implanted with a device similar to PEC-Direct, which contained a smaller amount of stem cell extract than PEC-direct. When the device was implanted in the human body, the progenitor cells it contained did grow into stem cells, but this clinical trial did not have enough cells to test whether the device could treat type 1 diabetes. Now, PEC-Direct has been implanted in the body of two patients. The pores outside it allow blood to flow into the patient's blood vessels and excite the progenitor cells. When the progenitor cells are activated (about 3 months), it secretes stem cells according to the patient's needs and detects the patient's blood sugar level. If this method works, patients do not need to check their blood sugar at all times, and do not need to perform any insulin implantation. However, they do need to take in the drugs to stop the immune system from destroying the newly created stem cells. For nearly two decades, a treatment that uses a similar concept has been applied worldwide, and patients are treated by implanting donor islet cells. However, the small number of donors has greatly affected the number of audiences for the therapy. "If the method is successful, it will completely change the treatment of type 1 diabetes worldwide," said Emily Burns of the British Diabetes Charity Association. For stem cells, we don't need to worry about inventory at all. In this trial, embryonic stem cells were derived from an early embryo (provided by a woman who gave births using IVF technology). Since the progenitor cells of PEC-Direct are derived from embryonic stem cells, they can be replicated indefinitely. Laikind said the method would treat all patients with type 1 diabetes. James Shapiro of the University of Alberta in Canada helped Viacyte in the research of the project and has already donated his own islet cells for diabetics. He said: "If the cells that produce insulin are produced in unlimited quantities, then this It will be a major advancement in the treatment of diabetes, which will be a great milestone in the history of treating diabetes." Original search "First implants derived from stem cells to 'cure' type 1 diabetes" Source: MIT Technology Review X Ray Lead Shield,Medical X Ray Lead Shield,X-Ray Shield Protection Lead,X - Ray Shielded Lead Longkou Kangxie Medical Instrument Co., Ltd , https://www.kangxiemedical.com